In 2022, over 600,000 people across the world were diagnosed with bladder cancer, a 7.1% increase from 2020, putting their ...

A biopsy reveals squamous cell carcinoma (SCC) in situ. What should be the next steps in the patient's evaluation and management? After the initial consultation, the patient's biopsy specimen was ...

For patients with ductal carcinoma in situ (DCIS), active monitoring (AM) is noninferior to guideline-concordant care (GCC) ...

Study reveals short term safety of active monitoring for ductal carcinoma in situ. ScienceDaily . Retrieved January 1, 2025 from www.sciencedaily.com / releases / 2024 / 12 / 241212115836.htm ...

SURGE Therapeutics (SURGE) is a provider of intraoperative immunotherapy services for cancer patients that offers an injectable biodegradable hydrogel and allows prolonged, localized free-up of most ...

BOSTON & MONTREAL, December 30, 2024--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage ...

Each year, more than 56,500 women are diagnosed with ductal carcinoma in situ (DCIS), a non-invasive type of breast cancer commonly referred to as Stage 0 breast cancer. A woman with DCIS is ...

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...

FRIDAY, Dec. 13, 2024 (HealthDay News) -- For patients with ductal carcinoma in situ (DCIS), active monitoring (AM) is noninferior to guideline-concordant care (GCC) that involves surgery with or ...

A new study, published in the New England Journal of Medicine, examines whether removing lymph nodes is always necessary in ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Investigators sought to determine the safety and accuracy of remote cutaneous confocal microscopy vs histopathological diagnosis of melanoma and keratinocyte carcinoma.